Obtenga las últimas noticias sobre las acciones de Vaccinex con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de VCNX

Últimas noticias sobre

Vaccinex

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Vaccinex Inc

Financing

Press Releases

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

News

Health Care

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024

General

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

Vaccinex Provides Update on ActivMAb® Platform:  Multiple Project Deals and Presentation at SITC

Earnings

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Markets

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

VCNX

Comments

Vaccinex Noticias bursátiles

Noticias

Últimas noticias sobre

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL